Syntex Board Changes

18 September 1994

- Syntex has elected three new board members appointed by the Roche group as part of its integration with the Swiss company. The Roche appointees are Armin Kessler, chief operating officer and head of Roche's pharmaceutical division, Peter Simon, head of the group's pharma operation and Kenneth Taylor, currently president and managing director of Roche Products in the UK. Meantime, resigning from the board were James Wilson, Dana Leavitt, Miriam Stoppard, Leonard Marks, Marvyn Carton, John Fried, Howard Holtzmann and Charles Lynch. The Syntex board elected Kenneth Taylor to succeed James Wilson as board president. Dr Taylor's successor in Roche UK will be Nic Holladay, the managing director of Syntex' UK and Ireland business.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight